| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12afed4734ab6704d0e69ceba9b80e27 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 |
| filingDate |
2015-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d37928380aa081bed167fa1a22c9d01 |
| publicationDate |
2017-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017360734-A1 |
| titleOfInvention |
Anti-rds compounds and method of manufacture and administration thereof to induce dopamine homeostatis |
| abstract |
Compounds for treating reward deficiency syndrome (RDS) behaviors and methods of use and administration of such compounds to induce dopamine homeostasis. These compounds synergistically combine two or more of (a) DP A, (b) NAC, and (c) kyotorphin (or arginine and tyrosine, the precursors of kyotorphin). These work together to enhance dopamine release by employing mechanisms tied to GABA regulation on Dorsal Raphe VGlut3 neurons via the Substania Nigra and increasing enkephalins (by increasing the release of enkepahlins and by the inhibition of enkephalinase). The resulting compound can induce dopamine homeostatis (and thus induce anti-stress states and diminish stress induced addictive behaviors). In embodiments of the present invention, the compound further includes nano-sized particles that enable the compound to be water- or powder-based even though DP A, NAC, and kyotorphin are not soluble in water. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10471034-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10973793-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10596136-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11602511-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11571404-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11129804-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10682325-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10660870-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10201513-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10238617-B2 |
| priorityDate |
2014-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |